Matti Annala

Prostate cancer genomics, plasma cell-free DNA biopsies, clinial trials, brain cancer genomics

Cancer genomics, computational biology

Jane and Aatos Erkko Foundation

Khalaf DJ*, Annala M*, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Optimal sequencing of enzalutamide and abiraterone plus prednisone in metastatic castration-resistant prostate cancer: a multi-centre, randomized, phase II trial. Lancet Oncology (in press, 2019).

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discovery, 8(4), 444-457 (2018).

Vandekerkhove GR*, Todenhöfer T*, Annala M*, Struss WJ, Wong A, Beja K, Ritch E, Brahmbhatt S, Volik S, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW. Circulating tumor DNA reveals clinically-actionable somatic genome of metastatic bladder cancer. Clinical Cancer Research 23, 6487-6497 (2017).

Wyatt A*, Annala M*, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. Journal of the National Cancer Institute, 109(12) (2017).

Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä I-L, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW. Treatment outcomes and tumor loss-of-heterozygosity in germline DNA repair deficient prostate cancer. European Journal of Urology 72(1), 34-42 (2017).

Annala M*, Kivinummi K*, Tuominen J, Karakurt S, Granberg K, Latonen L, Ylipää A, Sjöblom L, Ruusuvuori P, Saramäki O, Kaukoniemi K, Yli-Harja O, Vessella RL, Tammela TLJ, Zhang W, Visakorpi T, Nykter M. Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer. Oncotarget 6, 6235-6250 (2015).

The Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163, 1011-1025 (2015).

The Cancer Genome Atlas Working Group. The somatic genomic landscape of glioblastoma. Cell 155, 462-477 (2013).

Parker B*, Annala M*, Cogdell D, Granberg K, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, Yli-harja O, Haapasalo H, Visakorpi T, Liu X, Liu CG, Sawaya R, Fuller GN, Chen K, Lang FF, Nykter M, Zhang W. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. Journal of Clinical Investigation 123, 855-865 (2013).